Curi­um has set the list price for Bex­lutry, its ra­diosim­i­lar to No­var­tis’ Lu­tathera, at $63,524 per in­fu­sion — about a 5% dis­count to the cost...

The act­ing gen­er­al coun­sel at HHS, Bob Fos­ter, is no longer at the agency.

When End­points Newscon­tact­ed Fos­ter through his gov­ern­ment email, it re­ceived...

Pa­tients with the most com­mon KRAS mu­ta­tion in pan­cre­at­ic can­cer ap­peared to have a low­er re­sponse rate than the over­all pa­tient pop­u­la­tion with Rev­o­lu­tion Med­i­cines’...

At the start of 2026, Joshua Meier pitched his star­tup's col­lab­o­ra­tion with Eli Lil­ly as just the be­gin­ning.

Meier's vi­sion of a "year of de­ploy­ment"...

Plus news about Al­chemist Cap­i­tal, Newron Phar­ma­ceu­ti­cals, Life Bio­sciences, Onyx Bio and Tecen­triq.

City Ther­a­peu­tics charts $158M IPO: The RNAi start­up from for­mer Al­ny­lam ex­ec­u­tives...